Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial


First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small...

Related Keywords

United States ,Canada ,American , ,Facebook ,Twitter ,Instagram ,Statement Of Merck Co Inc ,Linkedin ,European Commission ,European Union ,Youtube ,American Joint Committee On Cancer ,Merck Research Laboratories ,Exchange Commission ,Merck Co Inc ,European Medicines Agency ,Medicinal Products ,Human Use ,American Joint Committee ,Marjorie Green ,Merck Research ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,